KISQALI 200 mg/1 (Ribociclib TABLET, FILM COATED) 200 mg/1

KISQALI 200 mg tablets are a pharmaceutical product used in cancer treatment. This oral medication is designed to support specific therapeutic protocols, offering a convenient film-coated tablet form for consistent dosing.

Strength

200 mg/1

Pack Size

1 BLISTER PACK in 1 CARTON (0078-0860-01) / 21 TABLET, FILM COATED in 1 BLISTER PACK

Manufacturer / TM Owner

Novartis Pharmaceuticals Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KISQALI 200 mg tablets are primarily used in the management of certain types of cancer. This medication is often incorporated into treatment plans to help control the progression of the disease. Patients may wonder, 'What is KISQALI used for?' Typically, it is prescribed as part of a broader therapeutic strategy to address specific cancer types.

Side Effects

Common effects of KISQALI 200 mg tablets may include gastrointestinal issues, fatigue, and changes in blood cell counts. Patients should monitor their body's response and consult their healthcare provider if they experience any unusual symptoms. The effects can vary widely among individuals, depending on their overall health and treatment plan.

Precautions & Warnings

Handling KISQALI 200 mg tablets requires careful consideration of individual health conditions. Patients with pre-existing liver or kidney issues should discuss their medical history with their healthcare provider. It is important to follow the prescribed dosage and administration guidelines to minimize potential risks.

Avoid Interactions

KISQALI 200 mg tablets may interact with certain medications, including those metabolized by the liver's CYP3A4 enzyme. Alcohol and other substances that affect liver function should be avoided unless approved by a healthcare provider. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.

References

Frequently Asked Questions

KISQALI is used in the treatment of certain types of cancer as part of a comprehensive therapeutic plan.

KISQALI tablets are taken orally, typically following a prescribed schedule. Patients should follow their healthcare provider's instructions for administration.

Common side effects may include gastrointestinal issues, fatigue, and changes in blood cell counts. Patients should monitor their body's response and consult their healthcare provider if they experience any unusual symptoms.

KISQALI may interact with certain medications, particularly those metabolized by the liver's CYP3A4 enzyme. Patients should inform their healthcare provider about all medications they are taking.

Patients with pre-existing liver or kidney issues should discuss their medical history with their healthcare provider. It is important to follow the prescribed dosage and administration guidelines.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.